Sciele Pharma Inc. is reporting the successful completion of a late-stage clinical trial of Glycopyrrolate.
This is a drug candidate designed to treat drooling in children with cerebral palsy and other neurological disorders.
This is a drug candidate designed to treat drooling in children with cerebral palsy and other neurological disorders.
The 24-week trial compared liquid Glycopyrrolate to a placebo.
According to the company, after eight weeks of taking the drug, patients drooled significantly less. The drug is intended to treat chronic moderate to severe drooling in children 3 to 18 with cerebral palsy, mental retardation, or any other neurological conditions.
According to the company, after eight weeks of taking the drug, patients drooled significantly less. The drug is intended to treat chronic moderate to severe drooling in children 3 to 18 with cerebral palsy, mental retardation, or any other neurological conditions.
There is no mention of any potential side effects associated with this drug.
Glycopyrrolate received orphan drug status from the FDA in 2006.
According to the source of this article, www.forbes.com ,Orphan drugs are designed to treat rare diseases, and they can be awarded market exclusivity for up to seven years if they are approved for sale.
According to the source of this article, www.forbes.com ,Orphan drugs are designed to treat rare diseases, and they can be awarded market exclusivity for up to seven years if they are approved for sale.
